NEW YORK, Nov. 11, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed against Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) and certain of its officers. This class action is on behalf of a class consisting of all persons who purchased Diplomat between October 9, 2014 and November 2, 2016, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"). The complaint alleges that throughout the Class Period, Defendants made false and misleading statements and/or failed to disclose that: (1) Diplomat lacked sufficient internal controls over its financial reporting; (2) consequently, Diplomat could not adequately calculate DIR fees; (3) Diplomat's hepatitis C segment was not performing as formerly released to shareholders; (4) as a result, Diplomat had exaggerated its 2016's full-year guidance; (5) and accordingly, Defendants' statements regarding its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. Following this news Diplomat stock dropped in value. No Class has yet been certified in the above action. To discuss this action, or for any questions, please visit the firm's site: http://www.bgandg.com/dplo or contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Diplomat, you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.